Is Ovid Therapeutics (OVID) One of the Best Fast Growing Penny Stocks to Buy According to Analysts? [Yahoo! Finance]
Ovid Therapeutics Inc. (OVID)
Last ovid therapeutics inc. earnings: 3/11 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.ovidrx.com
Company Research
Source: Yahoo! Finance
Capital initiated coverage of Ovid Therapeutics with an Outperform rating and set a price target of $4. Additionally, on December 18, Ovid Therapeutics Inc. (NASDAQ:OVID) announced successful Phase 1 results for OV350, the first-ever direct activator of the KCC2 transporter to be dosed in humans. The intravenous study met its primary objectives, showing a favorable safety and tolerability profile with no treatment-related serious adverse events or laboratory findings. Exploratory qEEG data further confirmed central activity and spectral power consistent with the expected physiological effects of KCC2 modulation in the brain. Photo by Robb Miller on Unsplash While the company does not plan to advance the intravenous OV350 further, these results validate the mechanism and support the development of its oral KCC2 portfolio. Ovid is now prioritizing OV4071, an oral activator that is 20x more potent than OV350 in disease models. The company remains on track to submit a regulatory app
Show less
Read more
Impact Snapshot
Event Time:
OVID
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OVID alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OVID alerts
High impacting Ovid Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
OVID
News
- Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots [Seeking Alpha]Seeking Alpha
- Ovid Therapeutics (NASDAQ:OVID) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OVID&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $4.00 price target on the stock.MarketBeat
- Ovid Therapeutics (NASDAQ:OVID) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.MarketBeat
- Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV) [Yahoo! Finance]Yahoo! Finance
OVID
Earnings
- 11/12/25 - Miss
OVID
Sec Filings
- 1/29/26 - Form SCHEDULE
- 1/8/26 - Form SCHEDULE
- 1/5/26 - Form 4
- OVID's page on the SEC website